PRGO Named Top 25 SAFE Dividend Stock Increasing Payments For Decades

Perrigo Company plc (PRGO) has been recognized on the "Dividend Channel S.A.F.E. 25" list, highlighting its robust dividend profile characterized by a solid return, consistent increases, an unblemished payment history, and over two decades of distributions. This pharmaceutical sector company, which is a constituent of the iShares S&P 1500 Index ETF (ITOT) and represents a 0.15% holding in the SPDR S&P Dividend ETF (SDY) valued at over $30 million, currently offers an annualized dividend of $1.16 per share.

Analysis

Perrigo Company plc (PRGO) has been recognized on the "Dividend Channel S.A.F.E. 25" list, underscoring its robust dividend characteristics. This designation highlights a solid return with a hefty yield and strong DividendRank, consistent dividend increases, and an unblemished history of never missing or lowering payments over two decades. The company currently pays an annualized dividend of $1.16 per share, distributed quarterly, with its most recent dividend ex-date noted as 08/29/2025.

Operating within the Drugs & Pharmaceuticals sector, PRGO's inclusion in the iShares S&P 1500 Index ETF (ITOT) and its 0.15% weighting in the SPDR S&P Dividend ETF (SDY), representing over $30 million, indicates its established market presence and appeal to dividend-focused funds. This positioning suggests a degree of stability and institutional confidence in its capital return policy.

The strongly positive sentiment (0.8 for PRGO, 0.75 overall) and bullish tone surrounding this news reflect the market's appreciation for companies demonstrating consistent shareholder returns, particularly within the defensive healthcare sector. Such a profile can attract long-term, income-oriented investors, potentially contributing to stable demand for the stock. The moderate market impact score of 0.4 suggests this news reinforces existing positive views rather than causing a dramatic shift.

Key Decisions for Investors

• Consider PRGO for income-focused portfolios due to its consistent dividend history and "S.A.F.E. 25" designation, which signals strong fundamental dividend quality.
• Monitor PRGO's performance within the Drugs & Pharmaceuticals sector, especially relative to peers, to ensure sustained dividend growth and fundamental strength.
• Evaluate the implications of its inclusion in dividend-focused ETFs like SDY, as this may provide a baseline of institutional demand and liquidity for the stock.